- Biovail has filed a $480 million lawsuit against Marion Merrell Dow claiming that the latter's lawsuit against Hoechst-Roussel, the firm to which Biovail licensed rights to a once-daily formulation of diltiazem, violates US antitrust laws. MMD has filed a number of lawsuits to prevent what it sees as violations of its patent on once-daily diltiazem.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze